Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationIn vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
Topological FDR for neuroimaging
Chumbley, J., Worsley, K., Flandin, G., & Friston, K. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.090 · Cited by 492
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · cited 3×
“Moreover, in another study, a significant linear rise of astrocytosis in the vicinity of neurofibrillary tangles was found with increasing Alzheimer’s disease progression, although this relationship was weaker than the one observed between astrocytosis and amyloid-b plaques.(55) Finally, in a study using autoradiograp…”
ResultOssenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472
Self-citationJohansen, J. S. (2006) · PubMed · Cited by 444
Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Self-citationThe role of astrocytes in amyloid production and Alzheimer's disease
Frost, G. R., & Li, Y.-M. (2017) · Open Biology · doi:10.1098/rsob.170228 · Cited by 435
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · cited 1×
“The following assays were used to measure the different biomarkers of interest to this study: GFAP Simoa Discovery kits for HD-X (QuanterixR ) for plasma GFAP; Elecsys assays (NeuroToolKit robust prototype, Roche Diagnostics) for CSF GFAP, YKL-40 and sTREM2; and Meso Scale Discovery immunoassays (MSD) for CSF amyloid-…”
MethodSelf-citationAstrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381
Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Self-citationAstrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355 · cited 2×
“activation induces a toxic inflammatory process that contributes to worsening Alzheimer’s disease progression.(51) Regardless of their Figure 4 Plasma GFAP shows early increases with amyloid-b-PET burden.”
BackgroundResultPalmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
Self-citationOeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero‐Rodriguez, J., Mattsson‐Carlgren, N., Schöll, M., Mecocci, P., Vellas, B., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12283 · Cited by 340
Self-citationCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
Ewers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
Self-citationCicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson-Carlgren, N., & Hansson, O. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 300
Self-citationYKL-40, a secreted glycoprotein, promotes tumor angiogenesis
Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., & Yan, W. (2009) · Oncogene · doi:10.1038/onc.2009.292 · Cited by 292
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282 · cited 2×
“This close relationship between astrocytes and plaques has been further supported by neuropathological reports showing that reactive astrocytes follow the same spatial distribution of amyloid-b plaques in the association cortex of patients with Alzheimer’s disease.(5,6) In contrast to the association between astrocyto…”
ResultVerberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258
Self-citationElahi, F. M., Casaletto, K. B., La Joie, R., Walters, S. M., Harvey, D., Wolf, A., Edwards, L., Rivera‐Contreras, W., Karydas, A., Cobigo, Y., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.004 · Cited by 255
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders
Carmona, S., Zahs, K., Wu, E., Dakin, K., Bras, J., & Guerreiro, R. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30232-1 · Cited by 244
Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony
Medeiros, R., & LaFerla, F. M. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.007 · Cited by 236
Rathcke, C. N., & Vestergaard, H. (2006) · Inflammation Research · doi:10.1007/s00011-006-0076-y · Cited by 216
Verberk, I. M. W., Laarhuis, M. B., van den Bosch, K. A., Ebenau, J. L., van Leeuwenstijn, M., Prins, N. D., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30061-1 · Cited by 202
Self-citationRemote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
Rajan, K. B., Aggarwal, N. T., McAninch, E. A., Weuve, J., Barnes, L. L., Wilson, R. S., DeCarli, C. S., & Evans, D. A. (2020) · Annals of Neurology · doi:10.1002/ana.25874 · Cited by 160
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Henjum, K., Almdahl, I. S., Årskog, V., Minthon, L., Hansson, O., Fladby, T., & Nilsson, L. N. G. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0182-1 · Cited by 143
Self-citationHulle, C. V., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andréasson, U., Okonkwo, O. C., Bendlin, B. B., Asthana, S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12204 · Cited by 139
Self-citationBeach, T. G., & McGeer, E. G. (1988) · Brain Research · doi:10.1016/0006-8993(88)90410-6 · Cited by 127
Lleó, A., Alcolea, D., Martínez‐Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa‐Neto, P., Slot, R. E. R., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.015 · Cited by 124
Self-citationBaldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
Meyer, S. D., Schaeverbeke, J. M., Verberk, I. M. W., Gille, B., Schaepdryver, M. D., Luckett, E. S., Gabel, S., Bruffaerts, R., Mauroo, K., Thijssen, E. H., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00728-w · Cited by 109
Self-citationEmerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91
Self-citationBourassa, P., Tremblay, C., Schneider, J. A., Bennett, D. A., & Calon, F. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01967-4 · Cited by 86
Asken, B. M., Elahi, F. M., Joie, R. L., Strom, A., Staffaroni, A. M., Lindbergh, C. A., Apple, A. C., You, M. Y., Weiner‐Light, S., Brathaban, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200755 · Cited by 84
CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum
Rauchmann, B., Schneider-Axmann, T., Alexopoulos, P., & Perneczky, R. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.022 · Cited by 78
Rodriguez-Vieitez, E., Carter, S. F., Chiotis, K., Saint-Aubert, L., Leuzy, A., Schöll, M., Almkvist, O., Wall, A., Långström, B., & Nordberg, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168732 · Cited by 76
Plasma YKL-40 in the spectrum of neurodegenerative dementia
Villar-Piqué, A., Schmitz, M., Hermann, P., Goebel, S., Bunck, T., Varges, D., Ferrer, I., Riggert, J., Llorens, F., & Zerr, I. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1531-3 · Cited by 73
Lemoine, L., Saint-Aubert, L., Nennesmo, I., Gillberg, P.-G., & Nordberg, A. (2017) · Scientific Reports · doi:10.1038/srep45496 · Cited by 57
Ikeda, K., Haga, C., Akiyama, H., Kase, K., & Iritani, S. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90820-w · Cited by 47
The history of neuromyelitis optica. Part 2: ‘Spinal amaurosis’, or how it all began
Jarius, S., & Wildemann, B. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1594-1 · Cited by 45
Ultrastructural and immunohistochemical study of degenerate neurite-bearing ghost tangles
Ikeda, K., Haga, C., Oyanagi, S., Iritani, S., & Kosaka, K. (1992) · Journal of Neurology · doi:10.1007/bf00839138 · Cited by 32
Asken, B. M., Elahi, F. M., Joie, R. L., Strom, A., Staffaroni, A. M., Lindbergh, C. A., Apple, A. C., You, M. Y., Weiner‐Light, S., Brathaban, N., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-219001 · Cited by 21
Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease
Thijssen, E. H., Verberk, I. M. W., Stoops, E., Boxer, A. L., & Teunissen, C. E. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.038179 · Cited by 19
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
Self-citationEmerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.